GSK Sues Watson Over Jalyn Generic

Parsippany, N.J.-based Watson Pharmaceuticals Inc. July 22 said that GlaxoSmithKline has sued it over its plans to market a generic version of GSK’s benign prostatic hyperplasia (BPH) treatment, Jalyn (dutasteride and tamsulosin hydrochloride capsules).

In a lawsuit filed July 21 in the U.S. District Court for the District of Delaware, GSK alleges that Watson’s abbreviated new drug application (ANDA) infringes GSK’s U.S. Patent No. 5,565,467 covering Jalyn, Watson said.

Watson said GSK is asking the court to block the Food and Drug Administration from approving Watson’s proposed generic before GSK’s patent expires. Under the Hatch-Waxman Act, the lawsuit’s filing triggers ...